echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Stone medicine is in full swing!

    Stone medicine is in full swing!

    • Last Update: 2022-01-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 5, 2022, NMPA released the latest drug approval information, and CSPC NBP Pharmaceutical's 3-type generic marketing application for zoledronic acid injection was approved, becoming the sixth domestic enterprise of this product
    .
    In addition, CSPC Zhongnuo Pharmaceutical (Shijiazhuang)'s 2.
    2 new drug listing application for mitoxantrone hydrochloride liposome injection has recently entered administrative approval, and good news is coming soon
    .

     
    Figure 1: The latest approved products of CSPC
    Source: NMPA official website
     
    Figure 2: Sales of zoledronic acid (unit: ten thousand yuan)
    Source: Minet.
    com China's public medical institutions terminal competition pattern
     
    Zoledronic acid can be used to treat hypercalcemia caused by malignancy, and in combination with standard antineoplastic drugs for the treatment of bone lesions in patients with bone metastases from solid tumors and in patients with multiple myeloma
    .
    According to the data of Minet.
    com, in 2018, the sales of zoledronic acid in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals have exceeded 2 billion yuan.
    It ranks first in the TOP20 drug varieties for the treatment of bone diseases , and the main dosage form on the market is injections
    .

     
    Figure 3: Zoledronic acid has previously reviewed companies
    Source: Minet Consistency Evaluation Database
     
      Zoledronic acid injection has been approved by 5 companies earlier, among which Yangzijiang, Kelun, Qilu, and Chia Tai Tianqing have been reviewed, and CSPC, the leading domestic echelon, has also won this large variety
    .
    In addition, zoledronic acid concentrated solution for injection has also been reviewed by 3 companies.
    If this variety becomes the target of the seventh batch of national mining, CSPC is expected to participate in the market competition
    .

     
      At present, the liposome preparations that have been listed in the domestic market include doxorubicin hydrochloride liposome injection, amphotericin B liposome for injection and paclitaxel liposome for injection, and doxorubicin hydrochloride liposome of CSPC In 2020, the total sales of plastid injection in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities has exceeded 2.
    5 billion yuan, and it has become the best-selling liposome preparation in China
    .
    At the same time, CSPC has continued to develop in the field of liposome research and development in recent years.
    In August 2020, the company was the first to apply for the listing of 2.
    2 new drugs for mitoxantrone hydrochloride liposome injection, which is used for relapse or relapse after at least first-line standard treatment in the past.
    For patients with refractory peripheral T-cell lymphoma, if the new drug is successfully approved, it is expected to become the second blockbuster liposome product under CSPC and the fourth liposome product in China
    .

     
      Figure 4: New clinical indications for mitoxantrone hydrochloride liposome injection that have been approved
      Source: CDE official website
     
      CSPC has placed high expectations on mitoxantrone hydrochloride liposome injection, and five new indications have been approved for clinical use
    .
    Phase Ib/II clinical trials of the new drug for acute myeloid leukemia are ongoing, and Phase I trials for relapsed/refractory multiple myeloma are also ongoing
    .
    It is foreseeable that the future market space will be huge with the approval of new indications after the product enters the market
    .
     
      Source: NMPA official website, CDE official website, Minet database
     
      The review data statistics are as of January 6.
    If there are any mistakes or omissions, please correct me
    .
      On January 5, 2022, NMPA released the latest drug approval information, and CSPC NBP Pharmaceutical's 3-type generic marketing application for zoledronic acid injection was approved, becoming the sixth domestic enterprise of this product
    .
    In addition, CSPC Zhongnuo Pharmaceutical (Shijiazhuang)'s 2.
    2 new drug listing application for mitoxantrone hydrochloride liposome injection has recently entered administrative approval, and good news is coming soon
    .

     
      Figure 1: The latest approved products of CSPC
      Source: NMPA official website
     
      Figure 2: Sales of zoledronic acid (unit: ten thousand yuan)
      Source: Minet.
    com China's public medical institutions terminal competition pattern
     
      Zoledronic acid can be used to treat hypercalcemia caused by malignancy, and in combination with standard antineoplastic drugs for the treatment of bone lesions in patients with bone metastases from solid tumors and in patients with multiple myeloma
    .
    According to the data of Minet.
    com, in 2018, the sales of zoledronic acid in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals have exceeded 2 billion yuan.
    It ranks first in the TOP20 drug varieties for the treatment of bone diseases , and the main dosage form on the market is injections
    .

     
      Figure 3: Zoledronic acid has previously reviewed companies
      Source: Minet Consistency Evaluation Database
     
      Zoledronic acid injection has been approved by 5 companies earlier, among which Yangzijiang, Kelun, Qilu, and Chia Tai Tianqing have been reviewed, and CSPC, the leading domestic echelon, has also won this large variety
    .
    In addition, zoledronic acid concentrated solution for injection has also been reviewed by 3 companies.
    If this variety becomes the target of the seventh batch of national mining, CSPC is expected to participate in the market competition
    .

     
      At present, the liposome preparations that have been listed in the domestic market include doxorubicin hydrochloride liposome injection, amphotericin B liposome for injection and paclitaxel liposome for injection, and doxorubicin hydrochloride liposome of CSPC In 2020, the total sales of plastid injection in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities has exceeded 2.
    5 billion yuan, and it has become the best-selling liposome preparation in China
    .
    At the same time, CSPC has continued to develop in the field of liposome research and development in recent years.
    In August 2020, the company was the first to apply for the listing of 2.
    2 new drugs for mitoxantrone hydrochloride liposome injection, which is used for relapse or relapse after at least first-line standard treatment in the past.
    For patients with refractory peripheral T-cell lymphoma, if the new drug is successfully approved, it is expected to become the second blockbuster liposome product under CSPC and the fourth liposome product in China
    .

     
      Figure 4: New clinical indications for mitoxantrone hydrochloride liposome injection that have been approved
      Source: CDE official website
     
      CSPC has placed high expectations on mitoxantrone hydrochloride liposome injection, and five new indications have been approved for clinical use
    .
    Phase Ib/II clinical trials of the new drug for acute myeloid leukemia are ongoing, and Phase I trials for relapsed/refractory multiple myeloma are also ongoing
    .
    It is foreseeable that the future market space will be huge with the approval of new indications after the product enters the market
    .
     
      Source: NMPA official website, CDE official website, Minet database
     
      The review data statistics are as of January 6.
    If there are any mistakes or omissions, please correct me
    .
      On January 5, 2022, NMPA released the latest drug approval information, and CSPC NBP Pharmaceutical's 3-type generic marketing application for zoledronic acid injection was approved, becoming the sixth domestic enterprise of this product
    .
    In addition, CSPC Zhongnuo Pharmaceutical (Shijiazhuang)'s 2.
    2 new drug listing application for mitoxantrone hydrochloride liposome injection has recently entered administrative approval, and good news is coming soon
    .

     
      Figure 1: The latest approved products of CSPC
      Source: NMPA official website
     
      Figure 2: Sales of zoledronic acid (unit: ten thousand yuan)
      Source: Minet.
    com China's public medical institutions terminal competition pattern
     
      Zoledronic acid can be used to treat hypercalcemia caused by malignancy, and in combination with standard antineoplastic drugs for the treatment of bone lesions in patients with bone metastases from solid tumors and in patients with multiple myeloma
    .
    According to the data of Minet.
    com, in 2018, the sales of zoledronic acid in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals have exceeded 2 billion yuan.
    It ranks first in the TOP20 drug varieties for the treatment of bone diseases , and the main dosage form on the market is injections
    .

    hospital hospital disease disease disease_
     
      Figure 3: Zoledronic acid has previously reviewed companies
      enterprise enterprise
      Source: Minet Consistency Evaluation Database
     
      Zoledronic acid injection has been approved by 5 companies earlier, among which Yangzijiang, Kelun, Qilu, and Chia Tai Tianqing have been reviewed, and CSPC, the leading domestic echelon, has also won this large variety
    .
    In addition, zoledronic acid concentrated solution for injection has also been reviewed by 3 companies.
    If this variety becomes the target of the seventh batch of national mining, CSPC is expected to participate in the market competition
    .

     
      At present, the liposome preparations that have been listed in the domestic market include doxorubicin hydrochloride liposome injection, amphotericin B liposome for injection and paclitaxel liposome for injection, and doxorubicin hydrochloride liposome of CSPC In 2020, the total sales of plastid injection in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities has exceeded 2.
    5 billion yuan, and it has become the best-selling liposome preparation in China
    .
    At the same time, CSPC has continued to develop in the field of liposome research and development in recent years.
    In August 2020, the company was the first to apply for the listing of 2.
    2 new drugs for mitoxantrone hydrochloride liposome injection, which is used for relapse or relapse after at least first-line standard treatment in the past.
    For patients with refractory peripheral T-cell lymphoma, if the new drug is successfully approved, it is expected to become the second blockbuster liposome product under CSPC and the fourth liposome product in China
    .

    Pharmacy Pharmacy Pharmacy Standard Standard Standard
     
      Figure 4: New clinical indications for mitoxantrone hydrochloride liposome injection that have been approved
     
      Source: CDE official website
     
      CSPC has placed high expectations on mitoxantrone hydrochloride liposome injection, and five new indications have been approved for clinical use
    .
    Phase Ib/II clinical trials of the new drug for acute myeloid leukemia are ongoing, and Phase I trials for relapsed/refractory multiple myeloma are also ongoing
    .
    It is foreseeable that the future market space will be huge with the approval of new indications after the product enters the market
    .
     
      Source: NMPA official website, CDE official website, Minet database
      Source: NMPA official website, CDE official website, Minet database
     
      The review data statistics are as of January 6.
    If there are any mistakes or omissions, please correct me
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.